AMGN stock news · Amgen
Get alerts for AMGN
Follow Amgen (AMGN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AMGNAmgen is still running a Phase III study for pegloticase to help patients with uncontrolled gout.
NeutralAmgen is continuing a Phase III gout study, but no results are reported. This update does not change the outlook for the company.
Barclays has raised its target price for Amgen to $400, up from $380.
NeutralBarclays raised its Amgen target from $380 to $400, but the new target remains below shares near $439. The report adds no company results, so it does not change Amgen's outlook.
AstraZeneca and Amgen's drug Tezspire helps many patients with eosinophilic esophagitis feel much better.
Good for AMGNAmgen’s shared Tezspire study showed much higher tissue healing than placebo, with benefits lasting through week 52. Common side effects matched approved uses, but the report does not say Tezspire is approved for this disease.
Ohio Rep. David Taylor purchased between $3,003 and $45,000 in Amgen shares.
NeutralAmgen's story reports a lawmaker's stock purchase, but gives conflicting value ranges and no company news. That alone does not change the company's outlook.
Today, there are big trades happening in 10 health care stocks.
NeutralThe article lists an Amgen put trade tagged bullish. One options trade, without news about the company's business, does not change its outlook.
Stocks fell today as oil prices hit $98, raising worries about inflation.
Bad for AMGNU.S. stocks declined as crude oil prices rose, leading to increased Treasury yields and speculation about potential Federal Reserve rate hikes. Amgen was notably impacted, dropping 9.6% after Novartis reported negative results for a competing drug, which also affected Stryker and other biotech stocks.
Why did Amgen's stock drop on Tuesday?
NeutralAmgen's stock fell 9.51% following disappointing Phase 3 data from Novartis regarding its Lp(a)-lowering drug, which could have implications for Amgen's own drug in development targeting the same biomarker.